by 
Hematopoietic stem cell transplantation involves transferring hematopoietic stem cells to help rebuild the patient’s blood and immune system that was destroyed by chemotherapy and radiation therapy. It is often used to treat blood cancers like leukemia and lymphoma. Research shows HSCT can help kill any remaining cancer cells and prevent cancer relapse. However, complications from HSCT like infections and graft versus host disease can be severe. Newer research focuses on enhancing the procedure through improved donor matching, better preparation regimens, using umbilical cord blood as an alternate stem cell source, and devising new anti-rejection strategies to improve patient outcomes. Increased research in these areas is expected to drive greater adoption of HSCT for treating various cancers in the future.
The global Hematopoietic Stem Cell Transplantation (HSCT) Market is estimated to be valued at US$ 2.88 Billion in 2023 and is expected to exhibit a CAGR of 11% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the major trends in the HSCT market is the increased use of haploidentical stem cell transplantation. Haploidentical transplantation involves the use of stem cells from a family member who is only a partial genetic match (typically a parent or sibling), making it easier to find a donor. Earlier, haploidentical transplants were associated with high rates of graft failure and graft-versus-host disease. However, new techniques like graft engineering and high-dose post-transplant cyclophosphamide are helping overcome these challenges. Many transplant centers have now adopted haploidentical transplantation as a routine option for patients without a matched donor. This has expanded the addressable patient population for HSCT significantly.
Porter’s Analysis
Threat of new entrants: The HSCT market has high costs associated with research and development, which poses a barrier for new companies.
Bargaining power of buyers: Individual buyers have limited bargaining power in the HSCT market due to health emergencies requiring transplant services.
Bargaining power of suppliers: Suppliers of stem cells and therapies have some bargaining power due to differentiated services offered in niche areas.
Threat of new substitutes: There is potential for development of new advanced therapies but stem cell transplant still remains the standard treatment option currently.
Competitive rivalry: The market is dominated by few players and remains a competitive space with continuous new product innovation and development of advanced therapies.
Key Takeaways
The global hematopoietic stem cell transplantation (HSCT) market is expected to witness high growth over the forecast period of 2023 to 2030. The global Hematopoietic Stem Cell Transplantation (HSCT) Market is estimated to be valued at US$ 2.88 Billion in 2023 and is expected to exhibit a CAGR of 11% over the forecast period 2023 to 2030.
Regionally, North America is expected to dominate the global HSCT market due to presence of major players and advanced healthcare facilities. Europe is also expected to grow significantly during the forecast period due to increased funding for stem cell research.
Key players operating in the HSCT market are Pluristem Therapeutics Inc., CellGenix GmbH, Regen Biopharma Inc., Lonza Group, Kiadis Pharma, Taiga Biotechnologies, Inc., Takeda Pharmaceutical Company Limited, Escape Therapeutics, Inc., Bluebird Bio, Inc., Talaris Therapeutics, Inc., Marker Therapeutics Inc., Stempeutics Research Pvt Ltd., CBR Systems Inc., Priothera Ltd., Eurobio Scientific Group, Otsuka America Pharmaceutical, Inc., Pfizer Inc., Sanofi, FUJIFILM Holdings Corporation.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
